Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, Herts AL10 9AB, UK.
Neomesia Mental Health, Villa Jolanda Hospital, 60035 Jesi, Italy.
Medicina (Kaunas). 2019 Aug 23;55(9):525. doi: 10.3390/medicina55090525.
Post-traumatic stress disorder (PTSD) is a common psychiatric disorder resulting from a traumatic event, is manifested through hyperarousal, anxiety, depressive symptoms, and sleep disturbances. Despite several therapeutic approaches being available, both pharmacological and psychological, recently a growing interest has developed in using cannabis and synthetic cannabinoids stems from their consideration as more efficient and better tolerated alternatives for the treatment of this condition. The present paper aims to evaluate the clinical and therapeutic potentials of medical cannabis and synthetic cannabinoids in treating PTSD patients.
A systematic electronic search was performed, including all papers published up to May 2019, using the following keywords (((cannabis[Title/Abstract]) OR (synthetic cannabinoids [Title/Abstract])) AND ((PTSD[Title/Abstract]) OR (Posttraumatic stress disorder[Title/Abstract]))) for the topics 'Cannabis', 'Synthetic Cannabinoids', 'PTSD', and MESH terms, on the PubMed, Cochrane Library, and Web of Science online databases. For data gathering purposes, PRISMA guidelines were followed. Results were organized into two groups, considering cannabis and synthetic cannabinoids as different therapeutic approaches for PTSD.
Present data show that cannabis and synthetic cannabinoids, both acting on the endocannabinoids system, may have a potential therapeutic use for improving PTSD symptoms, e.g., reducing anxiety, modulating memory-related processes, and improving sleep.
Even though the current literature suggests that cannabis and synthetic cannabinoids may have a role in the treatment of PTSD, there is currently limited evidence regarding their safety and efficacy. Therefore, additional research is needed in order to better understand the effectiveness and therapeutic usage of these drug classes and monitor their safety.
创伤后应激障碍（PTSD）是一种常见的精神障碍，由创伤事件引起，表现为过度警觉、焦虑、抑郁症状和睡眠障碍。尽管有多种治疗方法，包括药理学和心理学方法，但最近人们对使用大麻和合成大麻素越来越感兴趣，因为它们被认为是治疗这种疾病的更有效和更耐受的替代方法。本文旨在评估医用大麻和合成大麻素治疗 PTSD 患者的临床和治疗潜力。
系统地进行了电子检索，包括截至 2019 年 5 月发表的所有论文，使用以下关键词 (((大麻[标题/摘要])或(合成大麻素[标题/摘要]))和((创伤后应激障碍[标题/摘要])或(Posttraumatic stress disorder[标题/摘要])))进行检索，检索主题为“大麻”、“合成大麻素”、“PTSD”和 MeSH 术语，检索数据库为 PubMed、Cochrane 图书馆和 Web of Science 在线数据库。为了收集数据，遵循了 PRISMA 指南。结果分为两组，分别考虑大麻和合成大麻素作为 PTSD 的不同治疗方法。
目前的数据表明，大麻和合成大麻素都作用于内源性大麻素系统，可能具有治疗 PTSD 症状的潜在用途，例如减轻焦虑、调节与记忆相关的过程和改善睡眠。
尽管目前的文献表明大麻和合成大麻素可能在 PTSD 的治疗中发挥作用，但关于它们的安全性和疗效的证据有限。因此，需要进一步的研究，以更好地了解这些药物类别治疗的有效性和治疗用途，并监测它们的安全性。
